Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
six
months ended in Jun. 2026,
VISEN Pharmaceuticals paid€0.41 Mil more to buy back shares than it received from issuing new shares.
It received€0.00 Mil from issuing more debt.
It paid€0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
It received€0.00 Mil from paying cash dividends to shareholders.
It spent€0.25 Mil on other financial activities.
In all, VISEN Pharmaceuticalsspent€0.66 Mil on financial activities for the
six
months ended in Jun. 2026.
VISEN Pharmaceuticals (FRA:T06) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
VISEN Pharmaceuticals's issuance of stock for the
six
months ended in Jun. 2026 was €0.00 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
VISEN Pharmaceuticals's repurchase of stock for the
six
months ended in Jun. 2026 was €-0.41 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
VISEN Pharmaceuticals's net issuance of debt for the
six
months ended in Jun. 2026 was €0.00 Mil.
VISEN Pharmaceuticals received€0.00 Mil from issuing more debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
VISEN Pharmaceuticals's net issuance of preferred for the
six
months ended in Jun. 2026 was €0.00 Mil.
VISEN Pharmaceuticals paid€0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
VISEN Pharmaceuticals's cash flow for dividends for the
six
months ended in Jun. 2026 was €0.00 Mil.
VISEN Pharmaceuticals received€0.00 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
VISEN Pharmaceuticals's other financing for the
six
months ended in Jun. 2026 was €-0.25 Mil.
VISEN Pharmaceuticals spent€0.25 Mil on other financial activities.
VISEN Pharmaceuticals Cash Flow from Financing Related Terms
VISEN Pharmaceuticals Cash Flow from Financing Historical Data
* Premium members only.
The historical data trend for VISEN Pharmaceuticals's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VISEN Pharmaceuticals Cash Flow from Financing Chart
VISEN Pharmaceuticals Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
VISEN Pharmaceuticals's Cash from Financing for the fiscal year that ended in Dec. 2025 is calculated as:
Cash Flow from Financing for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was €19.54 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Financing of €19.54 Mil mean?
VISEN Pharmaceuticals (FRA:T06) has a Cash Flow from Financing of €19.54 Mil as of Jun. 2026. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for VISEN Pharmaceuticals and its competitors.
Is VISEN Pharmaceuticals' Cash Flow from Financing too high?
VISEN Pharmaceuticals' current Cash Flow from Financing is €19.54 Mil. Overall, VISEN Pharmaceuticals has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does VISEN Pharmaceuticals' Cash Flow from Financing compare to ZTS?
VISEN Pharmaceuticals' Cash Flow from Financing of €19.54 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Drug Manufacturers company?
A good Cash Flow from Financing depends on the Drug Manufacturers industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for VISEN Pharmaceuticals and its competitors. VISEN Pharmaceuticals's current Cash Flow from Financing is €19.54 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VISEN Pharmaceuticals stock overvalued right now?
VISEN Pharmaceuticals (FRA:T06) has a current Cash Flow from Financing of €19.54 Mil. The current Cash Flow from Financing is €19.54 Mil. VISEN Pharmaceuticals' overall GF Score™ is 7/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For VISEN Pharmaceuticals (FRA:T06), the current Cash Flow from Financing is €19.54 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
VISEN Pharmaceuticals is a late-stage, near-commercialization biopharmaceutical company focused on providing treatments in selected endocrinology diseases in China. It has one Core Product and two other pipeline drug candidates. Its Core Product, lonapegsomatropin, is a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency (PGHD), a common short stature in patients aged under 18 caused by insufficient growth hormone. TransCon CNP (navepegritide), one of its key drug candidates, is a long-acting prodrug of c-type natriuretic peptide for the treatment of achondroplasia (ACH), a short-limbed dwarfism that results in severe skeletal complications and comorbidities.
7GF Score
Get the complete analysis for FRA:T06
Cash Flow from Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:T06 has been successfully added to your 
